RnR Market Research adds new HCV Drugs market research
reports by GlobalData for US, Japan, Brazil China, France, Germany, Italy,
Spain and the UK with an in-depth analysis on the companies in these countries.
RnRMarketResearch.com now offers new market research reports
on the Hepatitis C Virus drug industry for US, Japan, Brazil China, France,
Germany, Italy, Spain and the UK with an in-depth analysis on the companies in
these countries. There is no effective vaccine against HCV, so the market is
driven by therapeutics. Currently, drug combinations containing pegylated
interferon (e.g., Roche’s Pegasys and Merck’s PegIntron) and ribavirin (e.g.,
Roche’s Copegus and Merck’s Rebetol) are used to treat HCV infection. Patients
infected with HCV genotype 1 can also have a protease inhibitor added to their
combination therapy, such as Merck’s Victrelis (boceprevir) or Vertex’s Incivek
(telaprevir).
In United States, the projected drivers of HCV drug market
growth include increased patient awareness of HCV, broader HCV screening
recommendations, the shift in American medicine toward preventative care, and
the launch of next-generation HCV therapies. The report “PharmaPoint: Hepatitis C Virus – United States Drug Forecast and Market
Analysis” (http://www.rnrmarketresearch.com/pharmapoint-hepatitis-c-virus-united-states-drug-forecast-and-market-analysis-market-report.html)
says Vertex’s Incivek is the current market leader. It was among the first DAA
HCV therapies launched in the US. Incivek’s improved efficacy over the previous
standard of care (i.e., peginterferon and ribavirin combination therapy) in the
treatment of the most prevalent HCV genotype in the US, HCV GT1, enabled the
drug to quickly capture the market. The adverse events associated with Incivek
therapy, such as life-threatening skin reactions, and the slow-progressing
nature of HCV, has resulted in many patients deciding to forego treatment in
order to wait for the launch of a more-tolerable HCV regimen.
Standard interferon drugs are the current market leader in
China as per the report “PharmaPoint:
Hepatitis C Virus – China Drug Forecast and Market Analysis” (http://www.rnrmarketresearch.com/pharmapoint-hepatitis-c-virus-china-drug-forecast-and-market-analysis-market-report.html).
Primary research done for this report revealed that Merck’s Intron A
(interferon alfa-2b) is the most commonly prescribed standard interferon in
China, but that Roferon-A (interferon alfa-2a) and Kadmon’s Infergen
(interferon alfacon-1) are also used frequently. Standard interferon requires
more-frequent dosing than peginterferon alpha, but standard interferon has been
able to retain its market share in China in the face of competition from
peginterferon due to its lower cost.
The anticipated drivers of growth of the HCV market in
Brazil include increasing awareness of the disease, the adoption of
non-invasive liver diagnostic tests, and the launch of next-generation HCV
therapies. The report “PharmaPoint:
Hepatitis C Virus – Brazil Drug Forecast and Market Analysis” (http://www.rnrmarketresearch.com/pharmapoint-hepatitis-c-virus-brazil-drug-forecast-and-market-analysis-market-report.html)
says Roche’s Pegasys (peginterferon alfa-2a) is the current market leader in
Brazil. Pegasys was launched in Brazil after Merck’s PegIntron (peginterferon
alfa-2b), but GlobalData believes that Pegasys was able to quickly dominate the
market due to a perceived better side effect profile and efficacy. Sales of
both Pegasys and PegIntron are projected to increase in Brazil as a result an
increase in the country’s HCV treatment rate. Sales of both drugs are also
expected to be boosted by their drug’s inclusion in triple therapies (i.e.,
DAA, peginterferon, and ribavirin).
“PharmaPoint:
Hepatitis C Virus – Japan Drug Forecast and Market Analysis” (http://www.rnrmarketresearch.com/pharmapoint-hepatitis-c-virus-japan-drug-forecast-and-market-analysis-market-report.html)
says Merck’s PegIntron (peginterferon alfa-2b) is the current market leader in
Japan. The current standard of HCV therapy in Japan is a combination of
interferon and ribavirin. The less-frequent dosing of peginterferon compared
with standard interferon (i.e., once a week compared with three times a week)
enabled peginterferon to quickly capture market share. In addition to standard
interferon, PegIntron directly competes for market share with Roche’s Pegasys
(peginterferon alfa-2a). GlobalData’s primary research revealed that
peginterferon market position is further bolstered by the frequent use of
interferon monotherapy in Japan.
Janssen’s Incivo is the current market leader in the UK
Hepatitis C Virus drug market as per the report “PharmaPoint: Hepatitis C Virus – United Kingdom Drug Forecast and
Market Analysis” @ http://www.rnrmarketresearch.com/pharmapoint-hepatitis-c-virus-united-kingdom-drug-forecast-and-market-analysis-market-report.html.
Incivo was among the first DAA HCV therapies launched in the UK. The regimen
had an improved efficacy compared with the previous standard of care for HCV
GT1, a combination of peginterferon and ribavirin. GlobalData assumes that
Incivo’s shorter duration of triple-therapy (i.e., DAA, peginterferon, and
ribavirin) compared with Merck’s Victrelis enabled it to outcompete Victrelis
for market share. Incivo and Victrelis are both associated with adverse events,
which has resulted in HCV-infected patients in the UK deciding to forego
therapy in order to await the launch of more-tolerable HCV therapies.
Other country reports
available on the Hepatitis C Virus drug market forecasts:
On the same lines, a
different but relevant report “PharmaPoint: Hepatitis C Virus – Current and
Future Players” @ http://www.rnrmarketresearch.com/pharmapoint-hepatitis-c-virus-current-and-future-players-market-report.html is a vital source of up-to-date
information with in-depth analysis on the companies in the rapidly growing HCV
Market. The report identifies and analyses the key companies shaping and
driving the global HCV market. The report provides insight into the competitive
HCV landscape, including new companies entering the market. Companies covered
in this report include Merck, Roche, Vertex, Janssen, Gilead, AbbVie,
Bristol-Myers Squibb, Boehringer Ingelheim, Mitsubishi Tanabe, GlaxoSmithKline,
Achillion, Scynexis, Idenix and Presidio. Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=101454.
Explore more reports on the Hepatitis Drugs Market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/hepatitis-drugs.
